Correlation between FOXP3, CD11c Protein Expression and Prognosis of Patients with Diffuse Large B-cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2021.01.017
- Author:
Yan-Bing LI
1
;
Zhi WANG
1
;
Hong-Bo ZUO
1
;
Li-Bo LI
2
Author Information
1. Department of Oncology, Jiujiang No.1 People's Hospital, Jiujiang 332000, Jiangxi Province, China.
2. Department of Oncology, TCM-Integrated Hospital of Southern Medical University, Guangzhou 510310, Guangdong Province, China,E-mail: hblm2014@163.com.
- Publication Type:Journal Article
- MeSH:
Forkhead Transcription Factors;
Humans;
Immunohistochemistry;
Lymphoma, Large B-Cell, Diffuse;
Prognosis;
Proteomics
- From:
Journal of Experimental Hematology
2021;29(1):104-108
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the correlation between FOXP3, CD11c protein expression and the prognosis of patients with diffuse large B-cell lymphoma (DLBCL).
METHODS:This study included 48 patients with DLBCL who were admitted to Jiujiang No.1 People's Hospital and TCM-Integrated Hospital of Southern Medical University from January 2015 to January 2019. The DLBCL tissues removed during the operation were collected as test specimens. The expression of FOXP3 and CD11c protein were detected by immunohistochemistry. The deadline for postoperative follow-up was December 31, 2019, and the patient's short-term efficacy (complete remission, partial remission) and progression-free survival were recorded.
RESULTS:FOXP3 protein was positively expressed in the nucleus, mostly focally or diffusely distributed, the FOXP3
CONCLUSION:In some patients with DLBCL, FOXP3 and CD11c expresse positively, and the positive expression rate is related to the clinical stage and international prognostic index score. The positive expression of FOXP3 and CD11c indicate a good prognosis.
